RxDoctor Payments Data

Klara Briskin, MD

Neurology · New York, NYNPI 1518127174

Payments from drug & device makers

$46,177in general payments, 2019–2025

Across 1,041 payments — averaging $44.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$23K
  • Biohaven Pharmaceutical Holding Company Ltd.$8K
  • Biohaven Pharmaceuticals, Inc.$4K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Pfizer$1K
  • MDD US Operations, LLC$940
  • plus $7K from 44 others

What the payments were for

  • Speaking & faculty fees$28,90063%
  • Travel & lodging$970%
  • Food & beverage$16,92137%
  • Education$2591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,177 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$168,265
Medicare patients
103
Services billed
14,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate15$28,710
UbrelvyUbrogepant15$17,427
HorizantGabapentin Enacarbil13$12,527
TrintellixVortioxetine Hydrobromide18$9,298
Fentanyl13$4,625
Doxepin Hcl19$4,179
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone24$4,134
Memantine Hcl ErMemantine Hcl12$742
Pregabalin30$613
Baclofen29$499
Duloxetine Hcl25$332
Pramipexole DihydrochloridePramipexole Di-Hcl24$325
Escitalopram Oxalate43$319
Gabapentin45$318
Levetiracetam22$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,318$28,71015 claims
AbbVieUbrelvy$22,670$17,42715 claims
Arbor Pharmaceuticals, Inc.Horizant$124$12,52713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$276$9,29818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →